NIH-AACR Cancer, Autoimmunity, and Immunology Conference
April 15-16, 2019 | Bethesda, MD

Elizabeth M. Jaffee, MD, AACR Past President, Deputy Director, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Elad Sharon, MD, MPH, Senior Investigator, National Cancer Institute
Connie Sommers, PhD, Program Director, National Cancer Institute
Howard Young, PhD, Principal Investigator, National Cancer Institute
Katarzyna (Kasia) Bourcier, PhD, Program Officer, National Institute of Allergy and Infectious Diseases
Marie Mancini, PhD, Program Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases

AGENDA: APRIL 15, 2019

9:00 AM Welcome

9:10 AM Opening Remarks
Ned Sharpless, MD, National Cancer Institute

9:25 AM Keynote Presentation: T-cell Co-stimulation in Autoimmune Diseases and Cancer
Arlene H. Sharpe, MD, PhD, Harvard University

GASTROINTESTINAL TOXICITIES
SESSION MODERATOR: MICHAEL DOUGAN, MD, PHD

10:00 AM GI Toxicities of Checkpoint Blockade
Michael Dougan, MD, PhD, Massachusetts General Hospital

10:20 AM Pancreatic Exocrine Related Diarrhea
Erez Baruch, MD, Sheba Medical Center, Tel Aviv

10:40 AM Gastrointestinal and Hepatic Complications of Immuno Checkpoint Inhibitors
Robert S. Bresalier, MD, MD Anderson Cancer Center

11:00 PM PANEL DISCUSSION

MOONSHOT ADMINISTRATIVE SUPPLEMENT AWARDEE UPDATE

11:25 AM Disruption of T cell tolerance in type 1 diabetes
Mark Anderson, MD, PhD, University of California, San Francisco

11:50 AM LUNCH BREAK

STEROID RESISTANCE/REFRACTORINESS

1:05 PM IVIG vs. Infliximab - steroid refractory pneumonitis
Jarushka Naidoo, MBbCh, Johns Hopkins University

1:30 PM Multidisciplinary irAE models
Kelly Walkovich, MD, C. S. Mott Children’s Hospital
NEUROLOGICAL AND OCULAR TOXICITIES
SESSION MODERATOR: DAVID HAFLER, MD, FANA

1:55 PM Unleashing the immune system in the brain
   David Hafler, MD, FANA, Yale School of Medicine

2:15 PM Severe cases of neurotoxicity associated with immune checkpoint treatment, strategies employed
   Bianca D. Santomasso, MD, PhD, Memorial Sloan Kettering Cancer Center

2:35 PM Ocular Toxicities
   Hatice Nida Sen, MD, MHS, National Eye Institute

2:55 PM PANEL DISCUSSION

3:20 PM BREAK

COMBINATION THERAPIES
SESSION MODERATOR: ELIZABETH JAFFEE, MD

3:40 PM Keynote Presentation: IO combination clinical trials
   Elizabeth M. Jaffee, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

4:10 PM Toxicities of radiation-immunotherapy combinations
   Jonathan D. Schoenfeld, MD, MPhil, MPH, Dana-Farber Cancer Institute

4:30 PM Regulatory perspective
   Nicole Drezner, MD, U.S. Food and Drug Administration

4:40 PM PANEL DISCUSSION

POSTER SESSION & RECEPTION

5:15-6:45 PM

6:45 PM ADJOURN
# NIH-AACR Cancer, Autoimmunity, and Immunology Conference

## AGENDA: APRIL 16, 2019

### 9:00 AM Welcome and Tribute to Stephen Katz

TBD

### SKIN TOXICITIES AND RHEUMATOLOGY

**SESSION MODERATOR: ROBERT CARTER, MD**

#### 9:05 AM Rheumatic adverse effects of immune checkpoint inhibitors

Xavier Mariette, MD, PhD, Bicetre Hospital, Paris-Sud University

#### 9:25 AM Development of Sjogren syndrome in the context of immune checkpoint inhibitors

Blake Warner, DDS, PhD, MPH, National Institute of Dental and Craniofacial Research

#### 9:45 AM Skin toxicities from immune checkpoint inhibitors

Nicole LeBoeuf, MD, MPH, Dana-Farber Cancer Institute

### 10:05 AM PANEL DISCUSSION

### 10:30 AM BREAK

### MOONSHOT ADMINISTRATIVE SUPPLEMENT AWARDEE UPDATE

#### 10:50 AM Regulation and function of nonlymphoid organ CD103 dendritic cells

Stephanie Watowich, PhD, MD Anderson Cancer Center

### META-ANALYSES

**SESSION MODERATOR: GIORGIO TRINCHIERI, MD**

#### 11:15 AM Mechanisms of autoimmunity association with cancer

Antony Rosen, MBChB, MD, Johns Hopkins Medicine

#### 11:35 AM Immune-related adverse events

Douglas B. Johnson, MD, Vanderbilt-Ingram Cancer Center

#### 11:55 AM Regulatory Perspective

Meredith Chuk, MD, U.S. Food and Drug Administration

### 12:15 PM LUNCH BREAK

### KEYNOTE ADDRESS

#### 1:30 PM Intro

Elizabeth M. Jaffee, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

#### 1:35 PM Microbiome immune-related adverse events

Jennifer Wargo, MD, MMSc, MD Anderson Cancer Center
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:05 PM</td>
<td>PANEL DISCUSSION – META-ANALYSES SPEAKERS AND DR. WARGO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:05 PM</td>
<td>CELL-BASED IMMUNOTHERAPY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:35 PM</td>
<td>Adverse Events of CAR-T Cell Therapy for Hematologic Malignancies</td>
<td>David L. Porter, MD, University of Pennsylvania Perelman School of Medicine</td>
<td></td>
</tr>
<tr>
<td>3:00 PM</td>
<td>CAAR-T for pemphigus vulgaris</td>
<td>Michael Milone, MD, PhD, University of Pennsylvania Perelman School of Medicine</td>
<td></td>
</tr>
<tr>
<td>3:25 PM</td>
<td>BREAK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:45 PM</td>
<td>PRE-CLINICAL MODELS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:45 PM</td>
<td>Autoimmunity following cancer treatment, more questions than answers</td>
<td>Jeff Bluestone, PhD, Parker Institute for Cancer Immunotherapy</td>
<td></td>
</tr>
<tr>
<td>4:05 PM</td>
<td>Evaluating IO Toxicities in Syngeneic Immunocompetent Mouse Models: Lessons, Opportunities and Challenges</td>
<td>Gregory L. Beatty, MD, PhD, University of Pennsylvania</td>
<td></td>
</tr>
<tr>
<td>4:25 PM</td>
<td>Human CTLA-4 Knock-in Mouse Model for irAE: Mechanism and Treatment</td>
<td>Pan Zheng, MD, PhD, University of Maryland, Baltimore</td>
<td></td>
</tr>
<tr>
<td>4:45 PM</td>
<td>Immune-mediated adverse events in humanized mice receiving checkpoint inhibitors</td>
<td>Kristina E. Howard, DVM, PhD, U.S. Food and Drug Administration</td>
<td></td>
</tr>
<tr>
<td>5:05 PM</td>
<td>PANEL DISCUSSION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:30 PM</td>
<td>WRAP-UP AND ADJOURN</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>